Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• TP53-mutated myeloid neoplasms (MN) present unique challenges due to their biology, treatment resistance, and poor prognosis.
• Prognostic impact of TP53 mutations varies based on disease status, mutation burden, and co-occurring genetic alterations.
• Existing prognostic models inadequately address the heterogeneity within TP53-mutated MN.

Purpose of the Study:

• To review the current understanding of TP53-mutated MN.
• To discuss evolving prognostic stratification strategies.
• To propose a clinical management framework and identify unmet needs.

Main Methods:

• Literature review of TP53-mutated myeloid neoplasms.
• Analysis of current prognostic models and therapeutic approaches.
• Discussion of novel therapeutic strategies and clinical trial designs.

Main Results:

• TP53-mutated MN are characterized by chemo-resistance and dismal outcomes.
• Novel therapies like p53 reactivators and anti-CD47 antibodies have shown limited success to date.
• Allogeneic stem cell transplantation remains the only option for long-term survival in select cases.

Conclusions:

• A comprehensive understanding of TP53-mutated MN is crucial for improved clinical management.
• There is a critical need for biologically informed clinical trials to enhance outcomes.
• Collaborative efforts are essential to develop effective strategies for this challenging disease.